RA Pathogenesis and Patient Goals
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting 1% of the population. If left untreated or undertreated, patients with RA can suffer from joint destruction as well as a wide array of debilitating extra-articular, systemic effects. This web-based interactive enduring activity will provide participants with the opportunity to optimize the treatment of patients with RA through improved knowledge about the role of cytokines, particularly IL-6, in pathogenesis and patient treatment. Furthermore, participants will be able to explore the importance of early and aggressive treatment of patients with RA and assess new data and recent treatment recommendation updates regarding the use of disease-modifying anti-rheumatic drugs (DMARDs) for treating patients with moderate-to-severe RA. This will enable them to better identify patients with RA in whom an IL-6 inhibitor or other non-TNFi therapy may be an appropriate treatment.
The goal of this activity is to provide rheumatologists and other healthcare professionals with valuable clinical insights that assess new and emerging therapies for patients with RA, including IL-6 inhibitors, and explore the effective use of these newer therapies in clinical practice.
This activity is intended for rheumatologists and other healthcare providers (physicians, nurse practitioners, and physicians’ assistants) who treat patients with RA.
Upon completion of this activity, participants will be better able to do the following:
- Discuss the importance of early and aggressive treatment of RA.
- Describe the role of cytokines, particularly IL-6, in the pathogenesis and treatment of RA.
- Assess new data and recent treatment recommendation updates regarding the use of DMARDs for moderate to severe RA.
Roy Fleischmann, MD, MACR (Chair)
Tsutomu Takeuchi, MD, PhD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
Roy Fleischmann, MD, MACR
Consultant/Advisor: Amgen Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Janssen Global Services, LLC; Pfizer Inc.; Sanofi-Regeneron; UCB Inc.
Grant/Research Support: Amgen Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Janssen Global Services, LLC; Pfizer Inc.; Sanofi-Regeneron; UCB, Inc.
Speakers’ Bureau: Pfizer Inc.
Tsutomu Takeuchi, MD, PhD
Consultant/Advisor: AbbVie Inc.; Asahi Kasei Corporation; Astellas Pharma Inc.; AstraZeneca; Bristol-Myers Squibb Company; Daiichi Sankyo Company, Limited; Eli Lilly and Company; Janssen Global Services, LLC; Merck KGaA; Mitsubishi Tanabe Pharma Corporation; Pfizer Inc.; Nippon Kayaku Co.,Ltd.; Takeda Pharmaceutical Company Limited
Grant/Research Support: AbbVie Inc.; Asahi Kasei Corporation; Astellas Pharma Inc.; AYUMI Pharmaceutical Corporation; Bristol-Myers Squibb Company; Chugai Pharmaceutical Co., Ltd; Daiichi Sankyo Company, Limited; Eisai Co., Ltd.; Taisho Pharmaceuticals Co., Ltd.; Takeda Pharmaceutical Company Limited
Speakers’ Bureau: AbbVie Inc.; Astellas Pharma Inc.; Bristol-Myers Squibb Company; Chugai Pharmaceutical Co., Ltd; Daiichi Sankyo Company, Limited; Eisai Co., Ltd.; Janssen Global Services, LLC; Mitsubishi Tanabe Pharma Corporation; Nippon Kayaku Co.,Ltd.; Pfizer Inc.
Non-faculty: Christina M. Ohnsman, MD; Jessica Marshall, PhD; Lou Settembrino; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Genzyme, a Sanofi Company and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Non-physician